Baseline characteristics

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer · Source last updated 2017-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      0

   2. group Id

      BG001

      value

      0

   3. group Id

      BG002

      value

      0

   4. group Id

      BG003

      value

      0

   5. group Id

      BG004

      value

      0

   units

   Participants

groups

1. description

   Patients receive palonosetron hydrochloride IV on day 1. palonosetron hydrochloride: Given IV

   id

   BG000

   title

   Arm I

2. description

   Patients receive palonosetron hydrochloride IV on days 1 and 4. palonosetron hydrochloride: Given IV

   id

   BG001

   title

   Arm II

3. description

   Patients receive placebo IV on day 1. placebo: Given IV

   id

   BG002

   title

   Arm III

4. description

   Patients receive placebo IV on days 1 and 4. placebo: Given IV

   id

   BG003

   title

   Arm IV

5. description

   Total of all reporting groups

   id

   BG004

   title

   Total

measures

1. title

   Age, Continuous

2. classes

   1. categories

      1. title

         Female

      2. title

         Male

   title

   Sex: Female, Male

population Description

Not enough patients were accrued. In order to avoid identification of patients, no results will be entered.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice